Spotlight on Fluvoxamine in Anxiety Disorders in Children and Adolescents

  title={Spotlight on Fluvoxamine in Anxiety Disorders in Children and Adolescents},
  author={Susan M. Cheer and David P. Figgitt},
  journal={CNS Drugs},
AbstractFluvoxamine is a selective serotonin reuptake inhibitor (SSRI) which may be used for the management of anxiety disorders in children and adolescents. Absorption of fluvoxamine was similar in adolescents to that in adults, which suggests that the maximum dosage of the drug for patients aged between 12 and 17 years can be as high as 300 mg/day. However, steady-state plasma fluvoxamine concentrations were 2 to 3 times higher in children (aged between 6 and 11 years) than in adolescents… 

Treatment of depression with selective serotonin inhibitors: the role of fluvoxamine

Fuvoxamine has a proven efficacy and safety profile in treating elderly patients with depression and its σ1-receptor binding profile may account for the observed high level of efficacy in psychotic depression and may explain the benefit of fluvoxamine in treating depression comorbid with anxiety/stress.

Pharmacogenetics of selective serotonin reuptake inhibitors in pediatric depression and anxiety.

All the pharmacogenetic studies conducted as yet on pediatric samples and compares them with available data on adult samples are reviewed, with an emphasis on serotonergic genes such as the serotonin transporter (5-HTT) and additional genes known to be active in the CNS.

Pharmacologic management of anxiety disorders in children and adolescents

The serotonin selective reuptake inhibitors are considered a first-line pharmacological treatment for anxiety disorders in children and adolescents, along with minimal side effects and good tolerability.

Selective serotonin reuptake inhibitor-induced sexual dysfunction in adolescents: a review.

  • A. Scharko
  • Medicine, Psychology
    Journal of the American Academy of Child and Adolescent Psychiatry
  • 2004
Although the incidences of nonsexual SSRI-induced adverse effects seemed to be similar for both adult and pediatric populations, only one male of 1,346 pediatric subjects receiving an SSRI reported sexual dysfunction.

Child and adolescent psychopharmacology update.

Relevant Issues in the Monitoring and the Toxicology of Antidepressants

The purpose of TDM for new-generation ADs leads more to the monitoring of patient compliance and special patient groups such as the elderly, patients with liver and kidney impairment, and patients with poor metabolism by CYP 450 and comedication with inhibitors and inducers of those enzymes.

[Comorbidity in attention deficit hyperactivity disorder].

The functional model of ADHD based on these functions and these structures enables us to understand the comorbidity with the above mentioned processes and to identify the associated problems in order to rationalise the psychological approach and pharmacological treatment employed.

Disordered Gambling in Adolescents

Clinicians are advised to be sensitive to behavioral risk factors and to screen for disordered gambling in high risk adolescents and to use a combination of CBT and MET, as well as medication for any comorbid psychiatric condition, is recommended.



Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group.

Fuvoxamine is an effective treatment for children and adolescents with social phobia, separation anxiety disorder, or generalized anxiety disorder and reduces symptoms of anxiety on the Pediatric Anxiety Rating Scale.

Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression.

Preliminary evidence suggests that short-term treatment of adolescents with fluvoxamine is relatively safe and may be effective for OCD and some affective spectrum symptoms.

Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders.

Fluvoxamine has demonstrated short term efficacy in the treatment of OCD, panic disorder, social phobia, PTSD and in a range of obsessive-compulsive spectrum disorders and appears to have a better tolerability profile.

Multiple-dose pharmacokinetics of fluvoxamine in children and adolescents.

The pharmacokinetic results suggest that children (especially females) have a higher exposure to fluvoxamine than adolescents, whereas adolescents and adults appear to have similar exposure to fluvoxamine.

Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial.

  • M. RiddleE. Reeve J. Walkup
  • Psychology, Medicine
    Journal of the American Academy of Child and Adolescent Psychiatry
  • 2001
Fuvoxamine has a rapid onset of action and is well tolerated and efficacious for the short-term treatment of pediatric OCD.

Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.

Fluoxetine has overall therapeutic efficacy comparable with imipramine, amitriptyline and doxepin in patients with unipolar depression treated for 5 to 6 weeks, although it may be less effective than tricyclic antidepressants in relieving sleep disorders in depressed patients.

Electrocardiographic findings during extended clinical trials of fluvoxamine in depression: one years experience.

Fluvoxamine treatment of depression for one year was not associated with any significant effect on the electrocardiogram (ECG).

Preclinical evidence on the psychotropic profile of fluvoxamine.

Results of studies of the mechanism of action of fluvoxamine in which drug discrimination tests were performed with rats and pigeons suggest that the flu voxamine stimulus is not (or is only to a very limited degree) dependent on activation of 5-HT1A receptors or 5- HT1B/1D receptors, or both.

A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine

The pharmacokinetic and pharmacodynamic interaction between fluvoxamine, a serotonin reuptake inhibitor, and alprazolam, a triazolobenzodiazepine, is assesed and the dosage of alpazolam should be reduced during co-administration with fluVoxamine.

Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients.

The data support that fluvoxamine, in a sample of healthy depressed outpatients, has little effect on cardiovascular function, and further study and clinical experience with this drug will be necessary before the full extent of its cardiac profile is known.